Ubs Group Ag Cingulate Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.52 - $0.98 $72 - $137	140 New	140 $0
Q1 2023 May 12, 2023	SELL	$0.91 - $1.85 $5,346 - $10,868	-5,875 Reduced 87.46%	842 $0
Q4 2022 Feb 08, 2023	SELL	$0.69 - $328.8 $5,768 - $2.75 Million	-8,360 Reduced 55.45%	6,717 $6,000
Q3 2022 Nov 10, 2022	BUY	$0.26 - $420.0 $3,920 - $6.33 Million	15,077 New	15,077 $16,000
Q1 2022 May 16, 2022	SELL	$278.4 - $698.4 $1.31 Million - $3.29 Million	-4,716 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$556.8 - $1068.0 $2.63 Million - $5.04 Million	4,716 New	4,716 $13,000

Ticker CING
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,309,400
Market Cap $53.8M
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.